These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 31791718)

  • 1. Distinct Regulatory and Effector T Cell Metabolic Demands during Graft-Versus-Host Disease.
    Hippen KL; Aguilar EG; Rhee SY; Bolivar-Wagers S; Blazar BR
    Trends Immunol; 2020 Jan; 41(1):77-91. PubMed ID: 31791718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging translational strategies and challenges for enhancing regulatory T cell therapy for graft-versus-host disease.
    Hippen KL; Hefazi M; Larson JH; Blazar BR
    Front Immunol; 2022; 13():926550. PubMed ID: 35967386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effect of donor CD4+CD25+ regulatory T cells on hematopoietic and immune reconstitution, GVHD and disease-free survival after allogeneic hematopoietic stem cell transplantation].
    Yang K; Fan ZP; Liu QF; Zhang Y
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Apr; 28(4):537-41. PubMed ID: 18495584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent Metabolic Advances for Preventing and Treating Acute and Chronic Graft Versus Host Disease.
    Mohamed FA; Thangavelu G; Rhee SY; Sage PT; O'Connor RS; Rathmell JC; Blazar BR
    Front Immunol; 2021; 12():757836. PubMed ID: 34712243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BET Bromodomain Inhibitors Which Permit Treg Function Enable a Combinatorial Strategy to Suppress GVHD in Pre-clinical Allogeneic HSCT.
    Copsel SN; Lightbourn CO; Barreras H; Lohse I; Wolf D; Bader CS; Manov J; Kale BJ; Shah D; Brothers SP; Perez VL; Komanduri KV; Wahlestedt C; Levy RB
    Front Immunol; 2018; 9():3104. PubMed ID: 30733722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modeling the interaction between donor-derived regulatory T cells and effector T cells early after allogeneic hematopoietic stem cell transplantation.
    Nishiyama N; Ruoff P; Jimenez JC; Miwakeichi F; Nishiyama Y; Yata T
    Biosystems; 2023 May; 227-228():104889. PubMed ID: 37019377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of regulatory T cells on the graft-versus-leukemia effect.
    Pacini CP; Soares MVD; Lacerda JF
    Front Immunol; 2024; 15():1339318. PubMed ID: 38711496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of regulatory T cells in graft-versus-host disease management.
    Whangbo JS; Antin JH; Koreth J
    Expert Rev Hematol; 2020 Feb; 13(2):141-154. PubMed ID: 31874061
    [No Abstract]   [Full Text] [Related]  

  • 9. Interleukin-27 Enforces Regulatory T Cell Functions to Prevent Graft-versus-Host Disease.
    Le HT; Keslar K; Nguyen QT; Blazar BR; Hamilton BK; Min B
    Front Immunol; 2020; 11():181. PubMed ID: 32117306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulatory T-cell suppression of CD8+ T-cell-mediated graft-versus-host reaction requires their presence during priming.
    Wang XN; Haniffa MA; Holtick U; Collin MP; Jackson G; Hilkens CM; Holler E; Edinger M; Hoffmann P; Dickinson AM
    Transplantation; 2009 Jul; 88(2):188-97. PubMed ID: 19623013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential Effect of MyD88 Signal in Donor T Cells on Graft-versus-Leukemia Effect and Graft-versus-Host Disease after Experimental Allogeneic Stem Cell Transplantation.
    Lim JY; Ryu DB; Lee SE; Park G; Choi EY; Min CK
    Mol Cells; 2015 Nov; 38(11):966-74. PubMed ID: 26552489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deletion of AMPK minimizes graft-versus-host disease through an early impact on effector donor T cells.
    Monlish DA; Beezhold KJ; Chiaranunt P; Paz K; Moore NJ; Dobbs AK; Brown RA; Ozolek JA; Blazar BR; Byersdorfer CA
    JCI Insight; 2021 Jul; 6(14):. PubMed ID: 34291733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biomarkers for acute and chronic graft-versus-host disease in regulatory T cells.
    Ukena SN; Geffers R; Buchholz S; Stadler M; Franzke A
    Transpl Immunol; 2012 Dec; 27(4):179-83. PubMed ID: 22889700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Responses of regulatory and effector T-cells to low-dose interleukin-2 differ depending on the immune environment after allogeneic stem cell transplantation.
    Meguri Y; Asano T; Yoshioka T; Iwamoto M; Ikegawa S; Sugiura H; Kishi Y; Nakamura M; Sando Y; Kondo T; Sumii Y; Maeda Y; Matsuoka KI
    Front Immunol; 2022; 13():891925. PubMed ID: 35983059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distribution and clonality of the vα and vβ T-cell receptor repertoire of regulatory T cells in leukemia patients with and without graft versus host disease.
    Jin Z; Wu X; Chen S; Yang L; Liu Q; Li Y
    DNA Cell Biol; 2014 Mar; 33(3):182-8. PubMed ID: 24410134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Control of GVHD by regulatory T cells depends on TNF produced by T cells and TNFR2 expressed by regulatory T cells.
    Leclerc M; Naserian S; Pilon C; Thiolat A; Martin GH; Pouchy C; Dominique C; Belkacemi Y; Charlotte F; Maury S; Salomon BL; Cohen JL
    Blood; 2016 Sep; 128(12):1651-9. PubMed ID: 27506541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advanced flowcytometric analysis of regulatory T cells: CD127 downregulation early post stem cell transplantation and altered Treg/CD3(+)CD4(+)-ratio in severe GvHD or relapse.
    Bremm M; Huenecke S; Lehrnbecher T; Ponstingl E; Mueller R; Heinze A; Bug G; Quaiser A; Kapinsky M; Brehm C; Bader P; Schneider G; Klingebiel T; Koehl U
    J Immunol Methods; 2011 Oct; 373(1-2):36-44. PubMed ID: 21839739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Helper T-cell differentiation in graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
    Fu J; Heinrichs J; Yu XZ
    Arch Immunol Ther Exp (Warsz); 2014 Aug; 62(4):277-301. PubMed ID: 24699629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulatory T-cells in the graft and the risk of acute graft-versus-host disease after allogeneic stem cell transplantation.
    Wolf D; Wolf AM; Fong D; Rumpold H; Strasak A; Clausen J; Nachbaur D
    Transplantation; 2007 Apr; 83(8):1107-13. PubMed ID: 17452902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mobilized Multipotent Hematopoietic Progenitors Promote Expansion and Survival of Allogeneic Tregs and Protect Against Graft Versus Host Disease.
    D'Aveni M; Notarantonio AB; Agbogan VA; Bertrand A; Fouquet G; Gastineau P; Garfa-Traoré M; De Carvalho M; Hermine O; Rubio MT; Zavala F
    Front Immunol; 2020; 11():607180. PubMed ID: 33643294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.